og体育
join us
CN
Home page
About Us
Profile
og体育:Affiliates/Subsidiaries
og体育:Development History
og体育:Quality Management
og体育:Contact Us
Legal Statement
og体育:Adverse Reaction Report
Science and Technology
R&D platform
R&D pipeline
Therapeutic Field
og体育:International Business
APIs
Finished Products
Medical device
Download product list
Contact
News Center
og体育:News & Trends
Public information
News & Trends
142023-12
Salubris' ღinnovative drugs Allisartan and Enarodustat® were enrolled into 2023 National Reimbursement Drug List(NRDL)
102023-10
New overseas clinical progress of JK0𒐪7 for the treatment of chronic heart failure (HFrEF)
082023-10
SAL0120 tablets for treatment of IgA nephropathy approved for cliꦺnical tri⛦al
102023-08
V🍰ena cava ജfilter system (SaExten®) approved by NMPA
092023-06
Enarodustat(ꦬ恩那罗®) Approved by NMPA for Treatment of Renal Anemia (Abstract) NMPA approved Enarodusta🅰t(恩那罗®)
052023-02
The clinical progre🍎ss of SAL0119 tablets for the treatment of ankylosing spond🍌ylitis and rheumatoid arthritis
目前在第
1
页,
共有
9
页,
共有
50
条记录
第一页
上一页
1
2
3
4
5
下一页
最后一页
跳转到
页
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7fDzSfyJvbjbD",ck:"K9y7fDzSfyJvbjbD"});
谈球吧体育(中国) - 官网app下载
OG体育(中国) - 官方网站
OG体育·(中国)平台
og体育(中国)- app下载